Inclusion Criteria:

          1. Patients with MDS according to WHO 2008 criteria (refractory anemia with multilineage
             dysplasia, RA (refractory anemia), refractory anemia with ringed sideroblasts (RARS)
             including CMML-1 (chronic myelomonocytic leukemia) type 1 with <10% blasts)

          2. low risk (IPSS-R very low, low and intermediate)

          3. in primary or secondary failure after erythropoiesis stimulating agents (ESAs),
             (either epoetins (≥60,000 units / week), or darbepoetin (≥250 μg / week), administered
             for at least 12 weeks, as defined by the IWG criteria 2006 (no erythroid response at
             12 weeks, or more than 15g / l decrease in Hb after response to ESAs) PS: Patients
             with low transfusion of less than (<) 4RBP assessed over 4 months (RBP administered
             for patients with Hb ≤ 9g / dl) will be accepted)

          4. age ≥ 18 years

          5. ECOG ≤2

          6. informed consent dated and signed

          7. affiliated to a social security scheme

          8. Women and men of childbearing potential must have effective contraception throughout
             the duration of the study and up to 4 days after the last administration of
             deferasirox

        Exclusion Criteria:

          1. Transfusion dependent patient (≥) 2 red blood cells (RBP) per 2-month period evaluated
             over 4 months between M-4 and M0

          2. Patients with high-risk MDS (based on IPSS-R) and patients with other hematologic and
             non-haematological malignancies who should not benefit from chelation therapy due to
             rapid progression of their disease

          3. Ferritin <200 ng / ml

          4. Iron overload: ferritin> 1000 ng / ml

          5. Creatinine clearance according to MDRD ≤60 ml / min

          6. 5q- deletion to karyotype

          7. Patient eligible for allograft

          8. Patient participating in another interventional clinical study or exclusion period
             from another study

          9. History of cancer treated or untreated for less than 5 years, whether or not there are
             signs of relapse or metastases, with the exception of basocellular cancers.

         10. Persons referred to in Articles L1121-5 to L1121-8 of the CSP: pregnant woman,
             parturient, mother who is breastfeeding, person deprived of liberty by judicial or
             administrative decision, person subject to a legal protection measure, can not not be
             included in clinical trials.